Product Code: RP-ID-10307074 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10307074
Market Overview:
Global Gaucher Disease Treatment Market Outlook 2027
Global Gaucher Disease Market Analysis – 2018-2027
Gaucher disease (GD) refers to the accumulation of glucocerebroside in cells and certain organs leading to the enlargement of the liver and spleen. The genetic disorder is caused by a hereditary deficiency of the enzyme glucocerebrosidase and is characterized by bruising, fatigue, anemia and low blood platelet count. The global Gaucher disease market is anticipated to record a CAGR of around 3% over the forecast period, i.e. 2019-2026. Factors such as increasing incidences of Gaucher’s disease as well as the increasing focus of the pharmaceutical companies on introducing new products that cater to the treatment of Gaucher disease are anticipated to contribute significantly towards the growth of the global Gaucher disease market. Additionally, increasing concern for the growing incidences of Gaucher disease amongst people around the globe, coupled with the growing support and funding of the government of nations and the rising per capita expenditure on healthcare by several nations around the globe are some of the factors anticipated to drive the growth of the global Gaucher disease market.
The global Gaucher disease market consists of various segments that are segmented by product type, by infusion mode, by clinical type, by end user and by region. The product type segment is further sub-divided into enzyme replacement therapy or ERT and substrate replacement therapy or SRT. Out of these, the enzyme replacement therapy segment, which held a market value of around USD 1400 million in the year 2018, is anticipated to grow with a CAGR of around 3% during the forecast period. On the basis of infusion mode, the market is segmented into intravenous infusion and oral. Out of these segments, the intravenous infusion segment is anticipated to hold the largest market share by the end of 2026 and is anticipated to grow with a CAGR of around 3% during the forecast period and reach a value of around USD 1600 million by the end of 2026.
Based on region, the global Gaucher disease market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in Europe, which had accounted for around 28% share in the year 2018, is estimated to witness a CAGR of around 2% during the forecast period and reach a value of around USD 520 million by the end of 2026.
Some of the affluent industry leaders in the global Gaucher disease market are Protalix Inc., Pfizer Inc., Actelion Pharmaceuticals Ltd., Sanofi and Takeda Pharmaceutical Company Limited.
Protalix Inc., Pfizer Inc., Actelion Pharmaceuticals Ltd., Sanofi and Takeda Pharmaceutical Company Limited
Related Reports
Proof of Quality & Reliability
